AU · rank #15 · 2026-10-23
AMLX
NASDAQ · $3.59B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.957 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.06 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 0 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.207 |
| Analyst upside Consensus target $43.00 | +50.5% |
| Momentum acceleration 3-month minus 12-month momentum. | +30.27% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.83 |
| Gross margin TTM | +13901.8% |
| 52w high | $41.14 |
| Market cap (USD) | $3.59B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Amylyx Pharmaceuticals is a biopharmaceutical company transitioning toward commercializing avexitide for post-bariatric hypoglycemia following the withdrawal of its former ALS product, Relyvrio [1, 2].
Rationale
The 50.5% analyst upside signal is backed by strong sell-side consensus (4.83/5 rating) and target raises following positive Phase 3 LUCIDITY trial results for lead candidate avexitide [1].
Material risks
- 1Potential FDA regulatory delays or rejection for lead asset avexitide would leave the company with no commercialized products or near-term revenue path [1, 2].
- 2Shareholder dilution from recent equity offerings and commercial execution risks in marketing to a newly defined post-bariatric hypoglycemia patient population [1].
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.